AnaptysBio (ANAB) Reiterated at Buy by UBS: Trial Now Set for July 2026

UBS analyst Michael Yee reiterated a Buy rating and $70.00 price target on AnaptysBio (NASDAQ: ANAB).

The analyst commented, "The Latest: ANAB announced they filed a motion to dismiss Tesaro/GSK's breach of contract claim in the ongoing litigation, which will be heard in early March. As a reminder, ANAB's suit claims GSK breached the collaboration agreement by seeking to combine their drugs with PD-1s other than Jemperli, such as Keytruda. GSK's suit claims (1) GSK/Tesaro did not breach the collaboration agreement and (2) AnaptysBio went against the agreement by suggesting GSK/Tesaro did. GSK's stance rests on the claim that ANAB repudiated the collaboration agreement by sending letters to initiate a process of dispute resolution. AnaptysBio's motion states these letters were sent through legal counsel in the interest of good faith resolution and therefore attempts to dismiss this claim. The trial to resolve all claims is now set for July 14-17, 2026."

For an analyst ratings summary and ratings history on AnaptysBio click here. For more ratings news on AnaptysBio click here.

Shares of AnaptysBio closed at $44.67 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy